Earnings Estimates Moving Higher for TransMedics (TMDX): Time to Buy?

Core Viewpoint - TransMedics (TMDX) is experiencing solid improvement in earnings estimates, which is likely to positively impact its stock price momentum [1][2]. Earnings Estimates - Current-quarter earnings are projected at $0.48 per share, reflecting a year-over-year increase of +37.14% [6]. - The Zacks Consensus Estimate for the current quarter has risen by 26.77% over the last 30 days, with four upward revisions and no negative changes [6]. - For the full year, earnings are expected to reach $1.90 per share, indicating a year-over-year growth of +88.12% [7]. - There has been a positive trend in estimate revisions for the current year, with four estimates moving up against one negative revision [7]. Zacks Rank - TransMedics currently holds a Zacks Rank 2 (Buy), indicating strong analyst agreement on upward earnings revisions [8]. - The Zacks Rank system has a proven track record, with Zacks 1 (Strong Buy) stocks averaging a +25% annual return since 2008 [3]. Stock Performance - TransMedics shares have increased by 43.3% over the past four weeks, suggesting strong investor confidence in its earnings growth prospects [9].